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Background: The epithelial cell adhesion molecule (EpCAM) has been shown to be overexpressed in breast cancer
and stem cells and has emerged as an attractive target for immunotherapy of breast cancer patients. This study
analyzes the effects of EpCAM on breast cancer cell lines with epithelial or mesenchymal phenotype.
Methods: For this purpose, shRNA-mediated knockdown of EpCAM gene expression was performed in EpCAMhigh
breast cancer cell lines with epithelial phenotype (MCF-7, T47D and SkBR3). Moreover, EpCAMlow breast carcinoma
cell lines with mesenchymal phenotype (MDA-MB-231, Hs578t) and inducible overexpression of EpCAM were used
to study effects on proliferation, migration and in vivo growth.
Results: In comparison to non-specific silencing controls (n/s-crtl) knockdown of EpCAM (E#2) in EpCAMhigh cell
lines resulted in reduced cell proliferation under serum-reduced culture conditions. Moreover, DNA synthesis under
3D culture conditions in collagen was significantly reduced. Xenografts of MCF-7 and T47D cells with knockdown of
EpCAM formed smaller tumors that were less invasive. EpCAMlow cell lines with tetracycline-inducible
overexpression of EpCAM showed no increased cell proliferation or migration under serum-reduced growth
conditions. MDA-MB-231 xenografts with EpCAM overexpression showed reduced invasion into host tissue and
more infiltrates of chicken granulocytes.
Conclusions: The role of EpCAM in breast cancer strongly depends on the epithelial or mesenchymal phenotype
of tumor cells. Cancer cells with epithelial phenotype need EpCAM as a growth- and invasion-promoting factor,
whereas tumor cells with a mesenchymal phenotype are independent of EpCAM in invasion processes and tumor
progression. These findings might have clinical implications for EpCAM-based targeting strategies in patients with
invasive breast cancer.
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The epithelial cell adhesion molecule (EpCAM, CD326)
is a transmembrane glycoprotein originally discovered as
a colon carcinoma-associated antigen [1]. The glycosy-
lated transmembrane protein consists of a 289 amino
acid extracellular domain (EpEX) and a short 26 amino
acid intracellular domain (EpICD) [2]. EpCAM localizes
to the basolateral membrane in normal polarized epithe-
lia, but in carcinoma this expression pattern changes to* Correspondence: gerold.untergasser@i-med.ac.at
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distribution, and reproduction in any mediuman intense uniform membranous overexpression that is
frequently associated with cytoplasmic staining [3]. In
addition, EpCAM is hyperglycosylated to a 40 kDa or
42 kDa isoform in carcinoma tissue as compared with
healthy autologous epithelia [4,5]. In breast carcinoma,
strong EpCAM expression is observed in less differen-
tiated tumors [6] and associates with larger tumors, nodal
metastasis and poorer overall survival [6-8]. Moreover, in
breast carcinoma EpCAM has been reported to be upre-
gulated in large metastases as compared with the matched
primary tumor [9]. Strong EpCAM expression has been
shown to be a poor prognostic factor in both node-
positive [8,9] and node-negative disease [6].tral Ltd. This is an Open Access article distributed under the terms of the
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cer cells need to develop a mesenchymal phenotype [10].
This change in cell morphology is known as epithelial to
mesenchymal transition (EMT) and seems to require
downregulation of tight junction proteins, EpCAM and
E-cadherin followed by re-expression at the site of the
future metastasis [11]. In breast cancer, EMT has been
estimated to occur in nearly 18% of tumors in vivo [12].
Under these conditions, EMT is defined as the occurrence
of a variable proportion of tumor cells that express mesen-
chymal markers, such as vimentin and tenascin [13,14].
EpCAM downregulation has already been associated
with EMT [15,16]. Small metastases in mice with colon
carcinoma were EpCAM-negative. In contrast, large me-
tastases in the same mouse displayed a level of expression
equal to that of the primary tumor, a finding that possibly
reflects the re-expression at the metastatic site [17].
This study analyzed different types of breast carcin-
oma cells derived from metastasis for their expression of
EpCAM. Based on EpCAM protein expression levels we
used lentiviral systems to knock down or induce
EpCAM gene expression. Knockdowns were done in
epithelium-like EpCAMhigh cell lines (T47D, MCF-7,
and SkBr3) and inducible overexpression was per-
formed in EpCAMlow cell lines (Hs578t, MDA-MB-231)
that display a mesenchyme-like phenotype. Our data
demonstrate that EpCAMhigh cancer cells with epithelial
morphology clearly benefit from EpCAM overexpression
with regard to proliferation and capacity to invade host
tissue. In contrast, in vitro proliferation of EpCAMlow
mesenchymal breast cancer cell lines is independent of
EpCAM. Furthermore, we provide evidence that in vitro
migration of tumor cells with mesenchymal phenotype is
weakly inhibited by overexpression of EpCAM. Similar
observations were made in vivo, where EpCAM-
overexpressing mesenchymal tumor cells showed reduced




MCF-7, T47D and SkBR3 cell lines were purchased from
the American Type Culture Collection (ATCC). All three
cell lines were isolated from metastasis and display an
epithelium-like phenotype. MCF-7, T47D cell lines were
cultivated in MEM, Eagle’s medium (PAA Laboratories
GmbH), and SKBR 3 in McCoy’s medium (PAA
Laboratories GmbH) containing 10% fetal calf serum
(PAA Laboratories GmbH) and 100 IU/mL penicillin,
100 μg/mL streptomycin and 2 mM glutamine (all
PAA Laboratories GmbH). MCF-7ns-ctrl, MCF-7E#2,
T47Dns-ctrl, T47DE#2, SkBR3ns-ctrl and SkBR3E#2 cell
lines were generated by lentiviral transfection with
the corresponding pGIPZ shRNA mir virus andselected with 3µg/mL puromycin (Invitrogen) for 5
days in standard culture medium.
Hs578t and MDA-MB-231 cells (ATCC) originate from
metastasis of human mammary carcinosarcoma and a
poorly differentiated adenocarcinoma, respectively. More-
over, the latter cell type is an elongated and a highly inva-
sive, metastatic phenotype. Hs578t and MDA-MB-231
cells were cultivated in RPMI1640 containing 10%
tetracycline-free FCS (Clontech). Parental lines of Hs578t
and MDA-MB-231 were lentivirally transfected
(pLENTI6/TR, Invitrogen) and selected with 1 mg/mL
neomycin (Biochrom) to express the tetracycline repressor
(TR) protein. Selected Hs578tTetR and MDA-MB-
231TetR lines were lentivirally transfected (pLenti6.3
EpCAM) and stable cell lines selected with 2 μg/mL
blasticidin (Invitrogen). Hs578tTetR EpCAM and MDA-
MB-231TetR EpCAM lines were propagated in 10%
tetracycline-free FCS (Clontech).
Immortalized non-tumorigenic human mammary epi-
thelial cells (MCF-10A) were obtained from the ATCC
and cultivated Dulbecco's modified Eagle's medium
F12 (DMEM/F12) supplemented with 5% horse serum
(both Invitrogen), 1% penicillin/streptomycin (all PAA
Laboratories GmbH), 0.5 μg/mL hydrocortisone, 10 μg/mL
insulin and 20 ng/mL recombinant human EGF (all Sigma
Biochemicals). Human Mammary Epithelial Cells (HMECs)
were purchased from Promocell. HMECs were cultivated
in Mammary Epithelial Cell Growth Medium with
recommended supplements (Promocell, 0.004 mL/mL
Bovine Pituitary Extract, 10 ng/mL epidermal growth
factor, 5 μg/mL insulin and 0.5 μg/mL hydrocortisone) on
collagen type I (Sigma Biochemicals) -coated ventilated
plastic flasks.
Immunohistochemistry
Tissue sections were deparaffinized and hydrated in
xylene and graded alcohol series. Antigen retrieval was
performed in a water bath (95°C) for 20 min with a target
retrieval solution (Dako Cytomation), and endogenous
peroxidase activity was blocked with 3% H2O2/methanol.
Sections were incubated in blocking solution containing
10% fetal calf serum (Dako Cytomation) for 45 min and
then stained for one hour with primary antibody (mouse
anti-human EpCAM, ESA, clone VU-1D9, Novocastra,
1 μg/mL). Moreover, serial sections were incubated with
an alpha smooth muscle cell actin (clone 1A4; 1:100,
Sigma Biochemicals) or Ki67 (clone MIB-1, Dako
Cytomation), or desmin (clone CD33, Dako), or
vimentin (clone V9, Dako), or E-cadherin (clone 32A8,
Cell Signaling Technology). Primary antiserum was
detected after incubation with a biotinylated secondary
antibody (biotinylated rabbit anti-mouse IgG, Vector
Laboratories Inc.) using the Vectastain Elite ABC Kit
(Vector Laboratories Inc.) and the FAST DAB Tablet Set
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Meyer’s hematoxylin and mounted with Pertex (Medite).
Immunofluorescence
Cells were seeded on eight-well culture chamber slides
(Falcon BD Labware) at densities of 20,000 cells/well
and incubated overnight in 5% CO2 at 37°C. After being
fixed in 4% paraformaldehyde and permeabilized with
0.2% Triton-X-100 cells were blocked with PBS con-
taining 3% BSA for 45 min at room temperature (RT).
E-cadherin- (clone 32A8, Cell Signaling Technology),
vimentin- (clone v9, Dako Cytomation), and cytokeratin
18- (clone DC 10, Dako) specific antibodies were applied
in a 1:200 dilution at RT for two hours. After washing in
PBS cells were incubated with secondary fluorochrome-
labeled antibodies (FITC-labeled rabbit anti-mouse, Dako
Cytomation) and nuclei were counterstained with DAPI
(Molecular Probes). Cells were embedded in fluorescent
mounting medium (Dako Cytomation) and viewed with
constant laser settings using a fluorescence microscope
(Zeiss Axiovert 200M with Axiovision 4.7 Software, Carl
Zeiss Optics).
Western Blot analysis
Cells were harvested and lysed in an RIPA buffer (Sigma)
containing protease inhibitors (Complete Mini EDTA-free;
Roche Applied Science). Total protein (20 μg) was denatu-
rated, separated by a 4%-20% SDS-PAGE (Criterion TGX,
Bio-Rad) and transferred to Immuno-Blot™ polyvinylidene
difluoride (PVDF) membrane (Bio-Rad). After blocking
the membrane in 5% non-fat milk powder dissolved in
phosphate-buffered saline (PBS), membranes were incu-
bated overnight in 0.5% non-fat milk powder at 4°C with
primary mouse antibodies. Antibodies used for Western
Blot analysis were a mouse monoclonal directed against
EpCAM (C-10; Santa Cruz Biotechnology) and a mouse
monoclonal against alpha tubulin (clone B5-1-2; Sigma
Biochemicals). Afterwards, membranes were incubated
for one hour with an HRP-conjugated goat anti-mouse
IgG (Dako Cytomation) diluted 1:1,000. After washing, a
chemoluminescent substrate (LumiGLO Reagent and Per-
oxide, Cell Signaling Technology) was added to the mem-
brane, which was then exposed in the Chemidoc XRS
station (Biorad Laboratories). Different glycosylated iso-
forms of EpCAM were analyzed by Western Blot after
deglycosylating the protein in RIPA buffer by means of
PNGase F and Endo H (both from New England Biolabs).
Band intensities were analyzed and calculated using the
Quantity One 4.6 software (BioRad Laboratories).
Generation of lentiviral particles for knockdown and
overexpression of EpCAM
Three lentiviral transfer vectors (pGIPZ shRNAmir) tar-
geting different regions of the EpCAM open readingframe (clone Ids: V2LHS_134162, V2LHS_134158,
V2LHS_23265) and validated non-silencing control
(ns-ctrl; RHS4346) were ordered from Open Biosystems.
pGIPZ clones were propagated in the presence of 25 μg/ml
zeocin (Invitrogen) and plasmids purified with the high-
speed Plasmid MIDI Kit (Qiagen). Lentiviral particles were
produced by transfecting HEK 293FTcells (Invitrogen) with
helper plasmid mix (trans-lentiviral packaging system,
Open Biosystems) and Lipofectamin 2000 (Invitrogen).
The EpCAM cDNA (NM_002354, Open Biosystems)
was subcloned into the Gateway pENTR11dual section
vector (Invitrogen). The pENTR11 vector was site-
specifically recombined with the pDEST6.3 vector
(Invitrogen) using the Gateway LR Clonase II Pus Enzyme
Mix (Invitrogen). The resulting pDEST6.3 vector with the
EpCAM open-reading frame was transformed and propa-
gated in One-Shot Stabl3 bacteria (Invitrogen). Lenti-
viruses were produced in HEK 293FT cells (Invitrogen)
by transfecting cells with the pDEST6.3 EpCAM vec-
tor and helper plasmid mix (ViraPower, lentiviral
support kit, Invitrogen) using Lipofectamine 2000.
Lentiviral titers were determined by real time PCR
and quantification of woodchuck hepatitis virus post-
transcriptional response element expression (WPRE-for:
5-actgacaattccgtggtgtt; WPRE-rev: 5-agatccgactcgtct
gagg), as described elsewhere [18].
Quantitative RT-PCR analysis
Total RNA was isolated from all cell lines using the
TriReagent (Sigma Aldrich), according to the manufac-
turer’s instructions. Thereafter, viral and genomic DNA in
the RNA samples was digested with the RQ1 DNAse
(Promega). The cDNA was amplified from 1 μg total
RNA using the SuperScript II Reverse Transcriptase
Kit (Invitrogen Life Technologies). For validation, real
time RT-PCR was performed using a SensiMix SYBR
No-ROX Kit (Bioline) and a Rotor-Gene 6000 detection
system (Corbett Research). Primers were designed to amp-
lify human-specific GAPDH (for: 5-ctgacctgccgtctagaaaa;
rev: 5-gagcttgacaaagtggtcgt), TATA-Box binding protein
(for: 5- ggagccaagagtgaagaaca; rev: 5-agcacaaggccttctaacct)
and EpCAM (for: 5-gctggtgtgtgaacactgct; rev: 5-
acgcgttgtgatctccttct).
Real time cell proliferation and migration assay
(xCelligence system)
Real time cell proliferation and migration experiments
were performed using the RTCA DP instrument (Roche
Diagnostics GmbH), which was placed in a humidified
incubator maintained at 5% CO2 and 37°C. For prolifera-
tion assays cells were seeded in complete medium in
16-well plates (E-plate 16, Roche Diagnostics GmbH) at a
density of 5,000 cells/well. The plate, which contained gold
microelectrodes on its bottom, was monitored every ten
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30 min until the end of the experiment, (72h). Cell
migration was performed using special 16-well plates with
8-μm pores (CIM plate 16, Roche Diagnostics GmbH).
These plates, resembling conventional transwells, have
microelectrodes on the underside of the membrane, which
is located between an upper and a lower chamber. Cells
were seeded into the upper chamber at a density of 20,000
cells/well in a serum-free medium. Lower chambers were
filled with complete medium. The plate was monitored
every 15 min for 12 h. Data analysis was performed using
the RTCA software 1.2 supplied with the instrument
(Roche Diagnostics).
3D tumor collagen plug formation
The ice-cold collagen type I solution was obtained by
mixing on ice 8.2 volumes of rat-tail collagen type I
(2.0 mg/ml, Sigma Aldrich), 1 volume of MEM 10x con-
centrated medium and 0.8 volumes of sterile 0.2 M
NaOH; pH was adjusted to 7.4 with sterile NaOH. 3D col-
lagen drop cultures were generated by resuspending 5.0 ×
105 breast cancer cells in 30 μl collagen mix. Hs578tTetR
EpCAM and MDA-MB-231TetR EpCAM cells were add-
itionally stimulated with tetracycline (1 μg/mL). Then
30 μl collagen drops were dropped into a sterile 10-cm, Ø
cell culture dish (Falcon) coated with sterilized parafilm
and allowed to polymerize for 30 min at 37°C in a
humidified cell culture incubator. After polymerization
of 3D cultures, collagen plugs were either transferred into
96-well plates (1 plug/well) and maintained in a 200 μL
standard complete cell culture medium for 3D in vitro cell
proliferation experiments or directly grafted on a chicken
CAM for in vivo tumor growth studies.
3D proliferation assay
MCF-7ns/ctrl, MCF-7E#2, T-47Dns/ctrl, T-47DE#2, SkBR3ns/ctrl,
SkBR3E#2 or Hs578tTetR EpCAM or MDA-MB-231TetR EpCAM
were grown in 96-well plates in the presence of 2.5%
serum. Hs578tTetR EpCAM or MDA-MB-231TetR EpCAM was
cultivated in complete medium with or without 1 μg/mL
tetracycline. After three days of in vitro growth a cell pro-
liferation assay was performed (BrdU ELISA kit, GE
Healthcare). Cells were pulsed with 5-bromo-2’-deoxyuri-
dine 20 h prior to measurement in ELISA. Microplates
with cell plugs were centrifuged at 2,000 g to allow the
plugs to attach to the bottom of the plate. Thereafter, cells
in plugs were fixed with the fixative solution and the ELISA
performed according to the manufacturer instructions.
Chicken chorioallantoic membrane (CAM) tumor
xenograft model
On embryo development day 0 fertilized chicken eggs
(Gallus domesticus) were placed in a 75%-80% humidified
37°C incubator to allow normal embryo development. Onday 3 eggs were opened, egg shells removed and embryos
were placed in a sterile Petri dish in an egg incubator
(Grumbach) to induce CAM development. Embryos were
inspected daily until the day of experiment. On day 8,
when the chorioallantoic membrane (CAM) and its vascu-
lature were well developed, the experiment was per-
formed. Subsequently, four onplants (collagen cell plugs)
per chicken were grafted onto the CAM. Growth of tumor
xenografts was inspected on a daily basis using a stereo
fluorescence microscope (Olympus SZW 10). On day 6
post-grafting chicken embryos were sacrificed by
hypothermia, xenografts/CAM cut out and stored in 4%
paraformaldehyde (Sigma Biochemicals) for immunohisto-
chemistry or in TRI reagent (Sigma Biochemicals) for
RNA isolation.
Statistical analyses
Statistical analyses were performed with the GraphPad
PrismTM software 5.0 (GraphPad Software, Inc.). All
tests of statistical significance were two-sided. Student’s
T test and the Mann–Whitney U Test were used to
study differences between two groups. Statistical ana-
lyses of quantitative PCR data were performed accor-
ding to the delta Ct method described by Pfaffl et al.
[19] and p values were calculated with Student's T test
or the two-way ANOVA test.
Results
Expression of EpCAM in breast cancer cell lines and
primary human mammary epithelial cells
EpCAM gene and protein expression was analyzed in
various breast cancer cell lines, immortalized (MCF-
10A) and normal mammary epithelial cells (HMECs).
Normal and immortalized cells showed no detectable
protein in Western Blot analysis (Figure 1A/B). The
same holds true for the mesenchyme-like breast cancer
cell lines MDA-MB-231 and Hs578t (Figure 1A/B). By
contrast, epithelium-like tumor cell lines MCF-7, T47D,
and SkBR3 showed strong expression of the EpCAM
protein as basic and glycosylated isoforms of 35 and 40
KDa (Figure 1A). Western Blot results were confirmed
by real-time PCR (Figure 1C). Epithelial breast carcin-
oma cell lines had significantly stronger EpCAM gene
expression than did HMECs or immortalized MCF-10A
mammary epithelial cells. Mesenchymal MDA-MA-231
and Hs578t displayed low amounts of EpCAM mRNA
(Figure 1C). Based on these findings EpCAMhigh and
EpCAMlow breast cancer cell lines were phenotyped for
markers of epithelial or mesenchymal differentiation.
MCF-7 and T47D cells with strong EpCAM expression
were strongly positive for epithelial markers cytokeratin
18 and E-cadherin and negative for mesenchymal vimen-
tin expression as determined by immunofluorescence ana-
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Figure 1 Expression of EpCAM in human breast cancer cell lines and primary epithelial cells. (A) Protein expression was analyzed by
Western Blot analysis with an antibody directed against the extracellular domain of EpCAM. Primary cells (HMECs) showed weak or no expression
of EpCAM. Epithelial tumor cells displayed strong EpCAM expression, whereas EpCAM expression decreased in more mesenchymal tumor cells.
The two different bands represent glycosylated and basic isoforms of EpCAM. Tubulin served as internal loading control. (B) Densitometric
analysis of EpCAM protein expression of two independent experiments. Values indicate relative intensity units. (C) EpCAM gene expression was
analyzed by real-time PCR analysis using TATA-Box binding protein and GAPDH as internal housekeeping genes. All cell lines were analyzed in
triplicate and normalized to the expression levels of MCF-10A cells. (D) Tumor cell lines were phenotyped by immunofluorescence analysis after
staining for epithelial markers cytokeratin-18 and E-cadherin and the mesenchymal marker vimentin. Magnification 400x.
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for the mesenchymal marker vimentin and negative or
weakly positive for E-cadherin and cytokeratin 18. Hs578t
cells were more transdifferentiated to mesenchymal can-
cer cells and more fibroblast-like than MDA-MB-231
(Figure 1D).Knockdown of EpCAM inhibited cell proliferation of
epithelium-like EpCAMhigh breast cancer cells in vitro
Based on our previous analysis of EpCAM expression in
epithelium- and mesenchyme-like breast carcinoma cell
lines we selected three EpCAMhigh cell lines for lentiviral
knockdown studies, i.e. T47D with a strongly glycosylated,
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basic EpCAM isoform (Figure 1A). Glycosylation patterns
were analyzed after deglycosylating all EpCAM isoforms
by means of endoglycosidases to a 35 kDa not glycosylated
isoform (data not shown). EpCAM-high cell lines were
lentivirally transfected to express a non-silencing control
(n/s ctrl) or EpCAM-specific shRNA together with turbo
GFP and a puromycin resistance gene (Figure 2A). Three
different sequences, E#1, E#2 and E#3 targeting the open
reading frame (ORF) of EpCAM, were pretested (data not
shown) and the E#2 sequence giving the best knockdown
was used for further studies. Effective knockdown was
controlled by real-time PCR on all three cell lines
(Figure 2B) and by Western Blot analysis (Figure 2C). Len-
tivirally transfected cells were selected for five days with
puromycin and subsequently used for analysis of cell pro-
liferation. In comparison to n/s ctrl cells, E#2 knockdown
cells displayed a significantly lower capacity to proliferate
in vitro after seeding the same starting amount of cells
into the xCelligence real-time cell counting system
(Figure 2D). These observations were made in all three
cell lines under serum-reduced conditions, i.e. 2.5%
serum, over the observed time period of three days. The
pro-survival effect of EpCAM was less pronounced under
full mitotic conditions, i.e. 10% serum in the culture
medium (data not shown). Additionally, cell proliferation
was analyzed by measuring DNA synthesis, i.e. BrdU in-
corporation, under 3D culture conditions in collagen
drops with tumor cells. All used cell lines displayed a sig-
nificant reduction in DNA synthesis after knockdown of
EpCAM within three days of in vitro growth (Figure 2E).
Knockdown of EpCAM inhibits invasion of epithelium-like
EpCAMhigh breast cancer cell xenografts
Based on our in vitro results we aimed to study the effects
of EpCAM knockdown in the in vivo situation. For this
purpose, we selected the chicken chorioallantoic mem-
brane (CAM) xenograft model that allows us to study
human cells in an animal microenvironment [20,21].
Chicken embryos have only innate immune responses and
tolerate growth of human cancer cells for a period of six
days when cells are transplanted on the surface of the
CAM tissue (Figure 3A). MCF-7 and T47D onplants can
be observed daily by stereo-fluorescence microscopy due
to expression of turbo GFP (Figure 3B). SkBr3 cells failed
to form vascularized tumors that invade the CAM (data
not shown). Macroscopically, MCF7 and T47D tumors
did not differ in size when analyzing and calculating only
surface areas on CAMs. Immunohistochemical analysis of
tumor cells by the proliferation marker Ki67 revealed that
knockdown of EpCAM significantly affected tumor cell
invasion into host tissue (Figure 3C). Knockdown of
EpCAM strongly reduced the invasion capacity of MCF-7
and T47D tumor cells in chicken tissue (Figure 3C, yellowline and arrows). Moreover, as determined by staining for
mesenchymal cells, such as pericytes (desmin) and smooth
muscle cells of chicken blood vessels (ASMA), reactive
responses of the chicken stroma to the invading tumor
cell front were nearly abolished (Figure 3C).
Overexpression of EpCAM does not support proliferation
or migration of mesenchyme-like EpCAMlow breast cancer
cells in vitro
Based on our previous analysis on EpCAM expression in
epithelium- and mesenchyme-like breast carcinoma cell
lines (Figure 1) we selected two EpCAMlow cell lines for in-
ducible lentiviral overexpression studies, i.e. MDA-MB-231
and Hs578t breast carcinoma cells, both with a mesenchy-
mal cancer phenotype (Figure 1D). Cells were lentivirally
transfected to express the bacterial tetracycline-repressor
protein (TET-R) and selected with neomycin for ten days.
Thereafter, MDA-MB-231TetR and Hs578tTetR cell lines
were lentivirally transfected with an EpCAM open reading
frame under a tetracycline-repressible CMV promoter
(Figure 4A) and short-time selected with blasticidin.
Both cell lines, MDA-MB-231TetR EpCAM and Hs578tTetR
EpCAM, were tested for tetracycline-induced expression of
EpCAM by real-time PCR (Figure 4B). In comparison to
cells growing without tetracycline and having low en-
dogenous transcript levels, addition of tetracycline
induced a 20- to 30-fold expression of the EpCAM gene.
In addition to gene expression, we also analyzed the in-
duction of EpCAM protein expression by Western Blot
analysis (Figure 4C). In both cell lines, MDA–MB-231TetR
EpCAM and Hs578tTetR EpCAM, we observed a strong induc-
tion of EpCAM protein already 24 h after adding tetracyc-
line to the culture medium (Figure 4D). It is noteworthy
that both cell lines produced predominantly the glycosy-
lated (40 kDa) isoform and, to a minor extent, also the
hyperglycosylated isoform (42 kDa). Tetracycline-
inducible EpCAM cell lines were used for analysis of
in vitro cell proliferation in the xCelligence system. Induc-
tion of EpCAM by tetracycline had no statistically signifi-
cant effect on cell proliferation within an observed time
period of three days (Figure 5A). Since Hs578t as well as
MDA-MB-231 cells show a high capacity to migrate, we
studied the effects of EpCAM on in vitro cell migration.
Cells were pre-incubated for 24 h with tetracycline,
counted and then transferred into the xCelligence real-time
cell migration system. Induction of EpCAM by tetracycline
did not affect in vitro cell migration within an observed
period of 12 h in MDA-MB-231 cells (Figure 5B). In con-
trast, the fibroblast-resembling Hs578t cells were signifi-
cantly inhibited in cell migration after overexpression of
EpCAM (Figure 5B). Analyses of DNA synthesis in the
BrdU incorporation assay of 3D collagen drop cultures also
did not reveal significant differences in in vitro cell prolif-
eration, three days after induction of EpCAM (Figure 5C).
MCF-7 SKBR-3 T47D 
EpCAM 
tubulin 
wt n/s E#2 wt n/s  E#2 wt n/s  E#2 
gccgtaaactgctttgtg – E#2 





CMV GFP IRES Puro shRNA









































































































































Figure 2 Lentiviral knockdown of EpCAM gene expression by shRNA in EpCAMhigh human breast cancer cell lines. (A) Lentiviruses were
generated that express not only the green fluorescent protein (GFP) and the puromycin resistance gene (Puro), but also shRNAs targeting EpCAM
(E#2) or a non-silencing control sequence (n/s ctrl). Transfected cells expressed turbo GFP and were selected with puromycin for five days. (B)
The efficacy of EpCAM knockdown (E#2) in comparison to that of non-silencing controls (n/s ctrl) was proven by real-time PCR. Gene expression
was reduced below 20% of the control value in all three cell lines analyzed. All cell types were analyzed in triplicate. (C) Knockdown of EpCAM
was proven on the protein level by Western Blot analysis. Tubulin alpha served as internal loading control. In comparison to wild-type cells (wt)
and n/s ctrl, EpCAM expression decreased in cells expressing E#2. Densitometric analysis of two independent experiments (means) as compared
to wild type expression (100%). (D) Proliferation of transfected cells was monitored in real-time by the xCelligence system over a period of 72 h.
E#2-expressing cells displayed significantly less proliferation and a smaller cell number when cultivated under serum-reduced conditions (n=6).
(E) 3D growth of transfected cells was studied in collagen plugs by incorporating BrdU and subsequently measuring BrdU in a specific ELISA.
E#2-expressing cells showed a significantly lower rate of DNA synthesis (n=6). Stars indicate p values < 0.05.
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Figure 3 Effects of lentiviral knockdown of EpCAM on in vivo growth and invasion of EpCAMhigh breast cancer cell lines. (A) In vivo
growth of MCF-7 breast cancer cell xenografts in the chicken chorioallantoic membrane model (CAM). Magnification 1x. (B) Xenografts form tumors
(arrow) that can be monitored due to expression of GFP by stereo-fluorescence microscopy. Within six days of observation tumors grew inside the
CAM and attracted and co-opted blood vessels. Magnification 20x. (C) Immunohistochemical analysis of tumor xenografts in the host tissue. Brown
color indicates a positive reaction. All nuclei were counterstained with hematoxylin (blue). Proliferating tumor cells were stained for the nuclear
antigen Ki67, mural cells of blood vessels (myofibroblasts) with alpha smooth muscle cell actin (ASMA) or pericytes (fibroblasts) with desmin.
Knockdown of EpCAM (E#2) resulted in tumors with less invasion and proliferation in host tissue and in a reduction of stromal responses to the tumor.
Yellow arrows indicate invading tumor cell clusters and yellow lines borders between xenograft and host tissue. (Magnification 200x). In vivo
experiments were performed with at least 12 embryos per group and 4 onplants/CAM. Asterisks indicate blood vessels of the underlying CAM.
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http://www.biomedcentral.com/1471-2407/12/501EpCAM downregulates E-cadherin gene expression in
mesenchyme-like EpCAMlow breast cancer cells
Depending on cell culture conditions and the respective
microenvironment, MDA-MB 231 cells with parentally
low EpCAM and E-cadherin expression can induce
endogenous transcription of both genes (Figure 6A/B).
The MDA-MB-231 cell line, when growing under 3Dculture conditions, displayed larger amounts of EpCAM
and E-cadherin than under standard 2-D culture condi-
tions. Transcript levels of E-cadherin and EpCAM were
even more elevated under in vivo culture conditions in
the CAM.
Interestingly, tetracycline-induced overexpression of
EpCAM in MDA-MB-231 cells was responsible for
MDA231 Hs578t















































































Figure 4 Inducible overexpression of EpCAM in EpCAMlow human breast cancer cell lines with mesenchymal phenotype. (A) EpCAMlow
cell lines MDA-MB-231 and Hs578t were transfected to express the tetracycline-repressor protein (TetR). A lentiviral construct for tetracycline
(T)-inducible expression of EpCAM was generated and tumor cells stably integrating the construct were selected and named Hs578tTetR EpCAM or
MDA-MB-231TetR EpCAM. (B) Stimulation with tetracycline for 24 h resulted in a strong induction of EpCAM gene expression as determined by real-
time PCR. Mean±SEM of three independent experiments. (C) Moreover, upregulation of EpCAM was observed on the protein level as determined
by Western Blot analysis. In addition to the unglycosylated protein, EpCAM was produced as a glycosylated and hyperglycosylated isoform in
both cell lines analyzed. (D) Densitometric analysis of EpCAM protein expression of two independent experiments. All means are calculated in
comparison to expression of MDA-MB 231 cells before induction with tetracycline.
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http://www.biomedcentral.com/1471-2407/12/501downregulation of E-cadherin gene expression, namely
under 3D conditions and in the CAM in vivo.
MDA-MB-231 xenografts with EpCAM overexpression
display reduced invasion into host tissue and strong
innate immune responses
Hs578tTetR EpCAM cells could not be used in the chicken
CAM xenograft model, because they did not invade
CAM tissue, lacked neovascularization and displayed
many apoptotic cells due to lack of oxygen and nutrients
(data not shown). Consequently, experiments were per-
formed with the highly invasive MDA-MB-231TetR EpCAM
cells. MDA-MB-231TetR EpCAM cells have low endogenous
EpCAM expression on the mRNA level, even without in-
duction with tetracycline (Figure 6A). Stimulation with
tetracycline in the collagen-graft resulted in an approx.
50-fold induction of EpCAM gene expression, as deter-
mined by real time PCR (Figure 6A). Interestingly, in vivo
MDA-MB-231 cells re-express E-cadherin, and EpCAMoverexpression represses E-cadherin gene expression
(Figure 6B). Macroscopically, tumors did not differ in size
after six days of in vivo growth (data not shown). We
therefore performed immunohistochemical analysis of
CAM sections to analyze changes on the cellular and tis-
sue level (Figure 7A-D). MDA-MB-231TetR EpCAM without
EpCAM overexpression were highly invasive, growing
deeply into host tissue and showed only dispersed cell
clusters that were weakly positive for EpCAM (Figure 7A).
By comparison, EpCAM-overexpressing tumors were
clearly positive for EpCAM protein expression and dis-
played an irregular invasion front into host tissue
(Figure 7A, red line). This front was also visualized by
staining for human tumor cells using cadherin
(Figure 7B). EpCAM-overexpressing tumors had no com-
pact and homogeneous invasion front into host tissue.
Moreover, when analyzing the proliferation marker Ki67
EpCAMlow tumors had a line of highly mitotic cells in the
invasion front that was nearly lost in EpCAMhigh tumors
















































































Figure 5 In vitro growth and migration of EpCAMlow human breast cancer cell lines after overexpression of EpCAM. (A) Cell numbers
were determined by the xCelligence real-time system after addition of tetracycline and incubation for three days (n=4). EpCAM overexpression
(EpCAM TET+) did not support in vitro cell proliferation under serum-reduced culture conditions. (B) In vitro cell migration was assessed with the
transwell CIM plate in the xCelligence real-time migration system 24 h after addition of tetracycline (n=4). MDA-MB-231TetR EpCAM cells showed no
significant (n.s.) changes in cell migration after overexpression of EpCAM (EpCAM TET+). In contrast, more mesenchymal Hs578tTetR EpCAM were
significantly inhibited by overexpression of EpCAM (EpCAM TET+). (C) Cell proliferation was studied in 3D collagen plug cultures after addition of
tetracycline and incubation for three days by measuring the incorporation of BrdU into synthesized DNA. Overexpression of EpCAM (EpCAM
TET+) had no significant (n.s.) impact on DNA synthesis in vitro (n=4). * indicates p value < 0.05.
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http://www.biomedcentral.com/1471-2407/12/501(Figure 7C). Inside tumors, the number of Ki67-positive
cells did not differ significantly. Additionally, we stained
mesenchymal human tumor cells for vimentin protein
expression (Figure 7D). EpCAMhigh tumors showed nodifferences in vimentin expression, suggesting that EpCAM
overexpression did not directly affect epithelial to mesen-
chymal transition (EMT). Moreover, EpCAMhigh tumors
showed more innate immune responses from the chicken
































































Figure 6 In vivo growth induces EpCAM and E-cadherin gene
expression. MDA-MB-231TetR EpCAM cells were grown in vitro in 3D
culture in collagen or in vivo in the chicken CAM. EpCAM (A) and
E-cadherin (B) gene expression was quantified relative to the low
expression levels in the parental cell line MDA-MB-231 (WT). RNA
was isolated 24 h after stimulation with tetracycline (TET+, n=4) or
without tetracycline (TET-, n=4) and analyzed by means of RT-qPCR.
Xenografts (n=4/group) were grown for five days in the chicken
embryo before isolation and analysis of RNA. Note, in vivo growth
induced EpCAM and E-cadherin expression in MDA-MB-231 cells.
EpCAM overexpression inhibited induction of E-cadherin gene
expression in MDA-MB-231 cells. * indicates p value ≤0.05.
Martowicz et al. BMC Cancer 2012, 12:501 Page 11 of 15
http://www.biomedcentral.com/1471-2407/12/501immune system. Heterophils (granulocytes) of the
chicken were recruited to the tumor invasion front
(blue line) and invaded in massive clusters between
tumor cells (Figure 7D, yellow arrows).
Discussion
EpCAM functions as a target in antibody-based clinical
trials, and the European Medicines Agency (EMA)
approved in 2009 the use of the trifunctional bispecific
antibody catumaxomab. In human breast cancer
patients, the EpCAM-specific antibody adecatumumab
shows EpCAM-dependent activity in clinical studies[22,23]. These antibodies bind to EpCAM and enhance
the immunological response to EpCAM-positive cancer
cells, either in blood or malignant ascites [24]. Moreover,
EpCAM has emerged as a promising target structure on
cancer stem cells [25]. Cancer stem cells expressing
EpCAM are more tumorigenic than EpCAM-negative
stem cells [11,26] and, due to their resistance to radi-
ation and chemotherapy, targeting EpCAM might be a
promising approach to impede tumor recurrence after
chemo- or radiotherapy.
Whether EpCAM has a pro- or an anti-tumorigenic
function in cancer appears to be dependent on the can-
cer type [11]. An ‘ugly’ role of EpCAM is reflected by
studies describing both a protective and a promoting
role within the very same cancer type [11]. Tumor con-
glomerates are very heterogeneous and contain distinct
cell types. Therefore, the role of EpCAM seems to depend
less on the carcinoma type, and more on the respective
tumor microenvironment [11]. Thus, EpCAM can shift
from a protective to a promoting role in cancer, depending
on the differentiation or dedifferentiation status of epithe-
lial cancer cells. The complex and hypothetical model of
action of the EpCAM molecule is summarized in Figure 8.
This study analyzed different breast cancer cell lines,
all deriving from breast cancer lymph node metastasis.
In particular, it analyzed the effects of EpCAM expres-
sion on cell lines according to their phenotype, i.e. the
status of epithelial to mesenchymal transition (EMT).
According to their EpCAM expression profile we used
lentiviral systems to alter endogenous gene expression
and studied the effects on in vitro and in vivo tumor
growth. Particularly, in breast carcinoma cells with high
cytokeratin-18 and E-cadherin expression, i.e. epithelial
phenotype, EpCAM displays growth- and invasion-
promoting effects. Our data are in line with reports on
pharyngeal, lung and breast cancer cells, where EpCAM
seems to support tumor progression [2,11]. Indeed, in
epithelial/acinar tumor cell lines with high cytokeratin
expression, such as the FaDu hypopharynx carcinoma
cells, EpCAM overexpression supports proliferation and
cell cycle by modifying Wnt signaling [27]. Moreover, a
recent study by Maghazal et al. showed that EpCAM
signaling is important during embryogenesis [28]. Inde-
pendently of its putative cell adhesion function, EpCAM
strongly supports cell movements and mixing of tissues
by a protein kinase C-dependent signaling mechanism.
Hs578t and MDA-MB-231 cells with a more mesen-
chymal phenotype do not gain survival benefits from
EpCAM overexpression or signaling. These cells typi-
cally have low EpCAM and E-cadherin expression and
display invasive growth and migration like reactive fibro-
blasts [10,29]. Our findings are in line with those of early
studies by Litvinov and colleagues on fibroblast-like
cells. They found that overexpression of EpCAM in vivo













Figure 7 Overexpression of EpCAM in MDA-MB-231 xenografts. MDA-MB-231TetR EpCAM cells were grafted into chicken embryos and in vivo
growth analyzed after five days in the presence and absence of tetracycline. In vivo experiments were performed with at least 12 embryos per
group and 4 onplants/CAM. (A) Cross-sections of tumor xenografts in host tissue were analyzed by immunohistochemistry for EpCAM protein.
Tumor invasion front into host tissue is indicated by a red line. (B) Tumor cells were stained for E-cadherin expression to indicate specifically
human tumor cells. (C) Proliferating human tumor cells were stained for the expression of Ki67. (D) Mesenchyme-like human tumor cells were
stained for the marker vimentin (vim). Note the massive clusters of chicken heterophils in EpCAM-high tumors (blue area) that incorporate
between tumor cells in the invasion front (yellow arrows). Magnification: 100 x.
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http://www.biomedcentral.com/1471-2407/12/501inhibited the invasive growth of fibroblastic L cells and
dedifferentiated mammary carcinoma L153S cells. More-
over, EpCAM overexpression suppressed invasive colony
growth of fibroblastic L cells in EHS matrigel in vitro
[30]. Interestingly, EpCAM overexpression did not
support mesenchymal-to-epithelial reverting transition
(MErT). However, MDA-MB-231 cells started to re-
express E-cadherin in vivo in our xenograft model, a factalready observed by Chao et al. [31]. This MErT process
was not affected by overexpression of EpCAM. Xenografts
still retained the high vimentin expression, but EpCAM-
overexpressing tumors displayed massive infiltrations of
chicken heterophils, which are avian analogs of mammalian
neutrophils [32]. In addition, few monocytes/macrophages
avian heterophils are recruited to areas of inflammation
and to the invading tumor cell front, thereby strongly
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Figure 8 Hypothetical model of the role of EpCAM in breast cancer. EpCAM function might switches from bad to good depending on the
phenotype of cancer cells, i.e. their status of epithelial to mesenchymal transition. More epithelium–like cancer cells with strong cytokeratin and
E-cadherin expression (T47D, MCF-7) need EpCAM to support proliferation, invasion and tumor angiogenesis. EpCAM knockdown results in fewer
invasive and angiogenic tumors in the chicken chorioallantoic membrane (CAM) xenograft model. GFP-positive tumor cells (T) can be monitored
on the CAM in real-time and obtain support via the blood vessels (red lines). In contrast, more mesenchyme-like tumor cells, having high
vimentin expression, grow independently of EpCAM. Overexpression of EpCAM in these cells disturbs invasion and tumor angiogenesis and
prompts strong innate immune responses by the chicken host (blue cells indicate heterophils).
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http://www.biomedcentral.com/1471-2407/12/501promoting angiogenesis [33]. Thus, EpCAM overex-
pression in mesenchyme-like tumors seems to stimu-
late inflammatory processes by activating and
attracting neutrophils to the invasion front. Tumor-
associated neutrophils (TANs) can promote the pro-
gression of primary tumors [34]. However, depending
on TGF-β signaling TAN can also differentiate into a
population with antitumor activity [35]. Recently, it
was reported that neutrophils in tumor-bearing sub-
jects can act to eliminate disseminated tumor cells
and thus provide antimetastatic protection [36].
Most importantly, all these findings might even have a
clinical impact since EpCAM-based targeting agents
(i.e. catumaxomab) are now available for therapeutic
use also in breast cancer patients [24]. In fact, breast
cancer is a frequent cause of malignant ascites and
especially invasive lobular breast cancer patients develop
peritoneal carcinomatosis with malignant ascites [37].
However, EpCAM expression is usually low in lobularbreast cancer as compared to ductal cancer [38], and
the phenotype of lobular breast cancer resembles that
of cancer cells undergoing EMT described in the
present study. Considering our data on an anti-
tumorigenic effect of EpCAM in mesenchyme-like can-
cer cells, targeting EpCAM in patients with lobular
breast cancer might even result in a counterproductive
effect. For this reason, particular attention should be
given to clinical studies determining the efficacy of
EpCAM-targeting agents in the subgroup of patients
with lobular breast cancer.
Conclusion
The role of EpCAM in breast cancer changes with
tumor cell phenotype and the respective tumor
microenvironment. Cancer cells with an epithelial
phenotype use EpCAM overexpression and signaling
for growth and invasion. In contrast, in tumor cells
with a mesenchymal phenotype EpCAM expression
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http://www.biomedcentral.com/1471-2407/12/501decreases and the tumor cells grow independently of
EpCAM signaling. Re-expression of EpCAM in these
tumors inhibits migration and invasion and promotes
inflammation and innate immune responses. There-
fore, the fact that EpCAM has a dual role in tumori-
genesis should be given consideration when planning
EpCAM-targeted therapies in breast cancer patients.
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